Takizawa Tsubasa, Kitano Takahiro, Togo Kanae, Yoshikawa Reiko, Iijima Masahiro
Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
Japan Access & Value, Pfizer Japan Inc., Tokyo, Japan.
PLoS One. 2024 Dec 19;19(12):e0315610. doi: 10.1371/journal.pone.0315610. eCollection 2024.
The real-world treatment patterns at medical facilities and their physicians' specialties treating migraine have not been fully investigated in Japan. Therefore, a retrospective cohort study aimed to describe real-world clinical practice and treatment patterns in Japanese patients with migraine according to medical facilities and physicians' specialties. Anonymized claims data of patients with migraine was obtained from JMDC Inc (January 2018-June 2023). Patient characteristics and treatment pattern according to medical facilities and physicians' specialties treating migraine were evaluated. Of 231,156 patients with migraine (mean age [SD], 38.8 [11.8] years; females, 65.3%), 81.8% had the first prescription at clinics (CPs), 42.5% underwent imaging tests, 44.4% visited general internal medicine, and 25.9% consulted neurosurgery at initial diagnosis. Imaging tests were carried out at CPs with specialists (59.4%), hospitals (HPs) with specialists (59.1%), HPs (32.9%), and CPs (26.9%) without specialists. Overall, 95.6% received acute treatment while 21.8% received preventive treatment. At facilities with specialists compared to without specialists, triptans were more frequently prescribed (67.9% vs 44.9%) whereas acetaminophen and nonsteroidal anti-inflammatory drugs were less frequently prescribed (52.4% vs 69.2%). Preventive treatment use was higher at facilities with specialists (27.4%) than without specialists (15.7%) and increased annually regardless of the type of medical institution. In Japan, only half of patients with migraine visited facilities with specialists at their first diagnosis, and specialists are more likely use migraine-specific and preventive drugs than nonspecialists. Therefore, there is a need for awareness among migraine patients that they should consult specialists and for enhancement of medical collaboration between specialists and nonspecialists.
在日本,医疗机构的实际治疗模式以及治疗偏头痛的医生专业情况尚未得到充分调查。因此,一项回顾性队列研究旨在根据医疗机构和医生专业描述日本偏头痛患者的实际临床实践和治疗模式。从JMDC公司获取了偏头痛患者的匿名索赔数据(2018年1月至2023年6月)。评估了根据治疗偏头痛的医疗机构和医生专业的患者特征及治疗模式。在231,156例偏头痛患者中(平均年龄[标准差],38.8[11.8]岁;女性,65.3%),81.8%在诊所(CPs)首次开具处方,42.5%接受了影像学检查,44.4%初诊时就诊于普通内科,25.9%咨询了神经外科。影像学检查在有专科医生的CPs(59.4%)、有专科医生的医院(HPs)(59.1%)、HPs(32.9%)以及没有专科医生的CPs(26.9%)进行。总体而言,95.6%接受了急性治疗,而21.8%接受了预防性治疗。与没有专科医生的机构相比,在有专科医生的机构中,曲坦类药物的处方频率更高(67.9%对44.9%),而对乙酰氨基酚和非甾体抗炎药的处方频率更低(52.4%对69.2%)。有专科医生的机构预防性治疗的使用率(27.4%)高于没有专科医生的机构(15.7%),且无论医疗机构类型如何,其使用率均逐年上升。在日本,只有一半的偏头痛患者在首次诊断时就诊于有专科医生的机构,并且专科医生比非专科医生更有可能使用偏头痛特异性药物和预防性药物。因此,偏头痛患者需要意识到应咨询专科医生,并且需要加强专科医生和非专科医生之间的医疗协作。